spacer
home > epc > spring 2017 > risky business
PUBLICATIONS
European Pharmaceutical Contractor

Risky Business

The globalisation of clinical trials and speciality pharmaceutical commercialisation, along with the rise of complex biologicalbased drug therapies, presents a host of opportunities for manufacturers. However, today’s mobile supply chain also comes with substantial risks. If overlooked, it can leave manufacturers, investors and an industry worth approximately $1.1 trillion exposed to potentially significant losses.

Managing the transportation of biopharmaceutical logistics cost almost $79 billion in 2016, with temperature-controlled products accounting for nearly $13 billion, according to Pharmaceutical Commerce’s annual Biopharma Cold Chain Sourcebook. With a growth rate of 8-9% year-on-year, spending on temperature-controlled logistics is predicted to rise to almost $17 billion by 2020, and the non-cold chain is estimated at $77 billion.

Such expense necessitates the identification and qualification of investment to mitigate mounting risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nils Markmann is Vice President of Global Operations at World Courier and is responsible for the daily management of their global operation in terms of networkwide implementation and adherence to global standards, as well as for ensuring consistent operational excellence throughout the company’s 140 offices. Formerly General Manager of Operations for World Courier Germany, Nils has been with the company since 1995.
spacer
Nils Markmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement